FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Newcomer

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Double-Blind Method

Activities & Behaviors

Schizophrenic Psychology

Physiology

Geographic Areas

United States

Co-author Network

Publications

TOP 3
Christina Mangurian; John W Newcomer; Felicia Rosario; Susan Essock; Carlos Jackson; Jonathan Amiel; Diane Barrett; Lucia Capitelli; Simriti Chaudhry; Francine Cournos; Michael Devlin
Implementation of a weight loss program for latino outpatients with severe mental illness.
Martin Thomas Strassnig; John W Newcomer; Philip D Harvey
Exercise improves physical capacity in obese patients with schizophrenia: pilot study.
Eric J Lenze; John W Newcomer; Elizabeth R Skidmore; Amy E Begley; Meryl A Butters; Ellen M Whyte
Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Newcomer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christina Mangurian; John W Newcomer; Felicia Rosario; Susan Essock; Carlos Jackson; Jonathan Amiel; Diane Barrett; Lucia Capitelli; Simriti Chaudhry; Francine Cournos; Michael Devlin
Implementation of a weight loss program for latino outpatients with severe mental illness.
Community mental health journal 2013;49(2):150-6.
2012: Martin Thomas Strassnig; John W Newcomer; Philip D Harvey
Exercise improves physical capacity in obese patients with schizophrenia: pilot study.
Schizophrenia research 2012;141(2-3):284-5.
2012: Eric J Lenze; John W Newcomer; Elizabeth R Skidmore; Amy E Begley; Meryl A Butters; Ellen M Whyte
Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.
International journal of geriatric psychiatry 2012;27(9):974-80.
2012: Elizabeth Pappadopulos; John W Newcomer; Sheela Kolluri
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
The Journal of clinical psychiatry 2012;73(6):e742-8.
2012: Eric J Lenze; Rose C Mantella; John W Newcomer; Charles F Reynolds; Carmen Andreescu; David Dixon; Peter M Dore; Meryl A Butters
Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.
International journal of geriatric psychiatry 2012;27(5):454-62.
2012: Julia M Gohlke; Elaine H Morrato; Henry A Nasrallah; John W Newcomer; Ginger Nicol; Gary Remington; Christoph U Correll; Stephen Crystal; Emily J Dhurandhar; David Allison
Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.
Frontiers in psychiatry / Frontiers Research Foundation 2012;3():62.
2011: marc de hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; David M Ndetei; John W Newcomer; Christoph Correll
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.
World psychiatry : official journal of the World Psychiatric Association (WPA) 2011;10(2):138-51.
2011: Jeffrey F Scherrer; Lauren D Garfield; Patrick J Lustman; Paul J Hauptman; Timothy Chrusciel; Angelique Zeringue; Robert M Carney; Kenneth E Freedland; Kathleen K Bucholz; Richard Owen; John W Newcomer; William R True
Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients.
The American journal of medicine 2011;124(4):318-24.
2011: marc de hert; Christoph Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.
World psychiatry : official journal of the World Psychiatric Association (WPA) 2011;10(1):52-77.
2011: Marianne Ulcickas-Yood; Mark J Cziraky; Gerald N Delorenze; Edward Kim; Robert D McQuade; John W Newcomer; Susan A Oliveria; Charles P Quesenberry; Ai-Lin Tsai; Gilbert J L'Italien
Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
BMC psychiatry 2011;11():197.
2011: Ginger E Nicol; Elaine H Morrato; Mark C Johnson; Elizabeth Campagna; Michael D Yingling; Victor Pham; John W Newcomer
Best practices: implementation of a glucose screening program based on diffusion of innovation theory methods.
Psychiatric services (Washington, D.C.) 2011;62(1):12-4.
2011: Elaine H Morrato; Benjamin G Druss; Daniel M Hartung; Robert J Valuck; Deborah Thomas; Richard Allen; Elizabeth Campagna; John W Newcomer
Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.
Pharmacoepidemiology and drug safety 2011;20(1):66-75.
2010: Christina Mangurian; Erin Goss; John W Newcomer
Metabolic screening and treatment preferences of Hispanic inpatients.
Psychiatric services (Washington, D.C.) 2010;61(11):1162-3.
2010: Stephen M Stahl; Ashok Malla; John W Newcomer; Steven G Potkin; Peter Weiden; Philip D Harvey; Antony Loebel; Eric J Watsky; Cynthia O Siu; Steve Romano
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Journal of clinical psychopharmacology 2010;30(4):425-30.
2010: Elaine H Morrato; Ginger E Nicol; David Maahs; Benjamin G Druss; Daniel M Hartung; Robert J Valuck; Elizabeth Campagna; John W Newcomer
Metabolic screening in children receiving antipsychotic drug treatment.
Archives of pediatrics & adolescent medicine 2010;164(4):344-51.
2010: Christina Mangurian; Elena Fuentes-Afflick; John W Newcomer
Risks from antipsychotic medications in children and adolescents.
JAMA : the journal of the American Medical Association 2010;303(8):729; author reply 730.
2010: Elaine H Morrato; Benjamin G Druss; Daniel M Hartung; Robert J Valuck; Richard Allen; Elizabeth Campagna; John W Newcomer
Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Archives of general psychiatry 2010;67(1):17-24.
2009: Marianne Ulcickas Yood; Gerald DeLorenze; Charles P Quesenberry; Susan A Oliveria; Ai-Lin Tsai; Vincent J Willey; Robert McQuade; John W Newcomer; Gilbert L'Italien
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Pharmacoepidemiology and drug safety 2009;18(9):791-9.
2009: Elaine H Morrato; John W Newcomer; Siddhesh Kamat; Onur Baser; James Harnett; Brian Cuffel
Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.
Diabetes care 2009;32(6):1037-42.
2009: John W Newcomer; Robert E Ratner; Jan W Eriksson; Robin Emsley; Didier Meulien; Frank Miller; Julia Leonova-Edlund; Ronald W Leong; Martin Brecher
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
The Journal of clinical psychiatry 2009;70(4):487-99.
2009: David Allison; John W Newcomer; Andrea L Dunn; James A Blumenthal; Anthony N Fabricatore; Gail L Daumit; Mark B Cope; William T Riley; Betty Vreeland; Joseph R Hibbeln; Jonathan E Alpert
Obesity among those with mental disorders: a National Institute of Mental Health meeting report.
American journal of preventive medicine 2009;36(4):341-50.
2009: Dan W Haupt; Lisa C Rosenblatt; Edward Kim; Ross A Baker; Richard Whitehead; John W Newcomer
Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.
The American journal of psychiatry 2009;166(3):345-53.
2009: Tim J R Lambert; John W Newcomer
Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care.
The Medical journal of Australia 2009;190(4 Suppl):S39-42.
2009: Elaine H Morrato; Brian Cuffel; John W Newcomer; Ilise Lombardo; Siddhesh Kamat; John Barron
Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
Journal of clinical psychopharmacology 2009;29(1):26-32.
2009: John W Newcomer
Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.
The Journal of clinical psychiatry 2009;70 Suppl 3():30-6.
2008: John W Newcomer; Jonathan M Meyer; Ross A Baker; James M Eudicone; Andrei Pikalov; Estelle Vester-Blokland; Robert D McQuade; David T Crandall; William H Carson; Ronald N Marcus; Gilbert L'italien
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
Schizophrenia research 2008;106(2-3):300-7.
2008: Jonathan M Amiel; Christina V Mangurian; Rohan Ganguli; John W Newcomer
Addressing cardiometabolic risk during treatment with antipsychotic medications.
Current opinion in psychiatry 2008;21(6):613-8.
2008: Ginger Nicol; John W Newcomer
Review: children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events.
Evidence-based mental health 2008;11(3):81.
2008: John W Newcomer; Joao Alberto Campos; Ronald N Marcus; Christopher Breder; Robert M Berman; Wendy Kerselaers; Gilbert J L'Italien; Marleen Nys; William H Carson; Robert D McQuade
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
The Journal of clinical psychiatry 2008;69(7):1046-56.
2008: John W Newcomer; Henry A Nasrallah; Roger S McIntyre; Roger S McIntyre; Suzanne Vogel-Scibilia
Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations.
CNS spectrums 2008;13(6 Suppl 10):13-4.
2008: John W Newcomer
Introduction: cardiovascular disease and metabolic risk factors in patients with mental illness.
CNS spectrums 2008;13(6 Suppl 10):1-14.
2008: W Wolfgang Fleischhacker; Marcelo Cetkovich-Bakmas; marc de hert; Charles H Hennekens; Martin Lambert; Stefan Leucht; Mario Maj; Roger S McIntyre; Dieter Naber; John W Newcomer; Mark Olfson; Urban Osby; Norman Sartorius; Jeffrey A Lieberman
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.
The Journal of clinical psychiatry 2008;69(4):514-9.
2008: Peter Weiden; John W Newcomer; Antony D Loebel; Ruoyong Yang; Harold E Lebovitz
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(5):985-94.
2008: Elaine H Morrato; John W Newcomer; Richard R Allen; Robert J Valuck
Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.
The Journal of clinical psychiatry 2008;69(2):316-22.
2007: Dan W Haupt; Peter A Fahnestock; Karen A Flavin; Julie A Schweiger; Angela Stevens; Martha J Hessler; Justin Maeda; Michael Yingling; John W Newcomer
Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(12):2561-9.
2007: John W Newcomer
Metabolic syndrome and mental illness.
The American journal of managed care 2007;13(7 Suppl):S170-7.
2007: John W Newcomer; Charles H Hennekens
Severe mental illness and risk of cardiovascular disease.
JAMA : the journal of the American Medical Association 2007;298(15):1794-6.
2007: Donald C Goff; John W Newcomer
Integrating general health care in private community psychiatry practice.
The Journal of clinical psychiatry 2007;68(7):e19.
2007: John W Newcomer; Michael J Sernyak
Identifying metabolic risks with antipsychotics and monitoring and management strategies.
The Journal of clinical psychiatry 2007;68(7):e17.
2007: Joseph J Parks; John W Newcomer
Implementing evidence-based medicine: lessons from public mental health settings.
The Journal of clinical psychiatry 2007;68(6):e16.
2007: Rohan Ganguli; Betty Vreeland; John W Newcomer
Monitoring and managing weight gain in the mentally ill.
The Journal of clinical psychiatry 2007;68(6):e14.
2007: Peter J Wieden; John W Newcomer
Evidence of switching antipsychotic therapy to improve metabolic disturbances.
The Journal of clinical psychiatry 2007;68(5):e13.
2007: Charles H Hennekens; John W Newcomer
Series introduction and cardiovascular disease in patients with schizophrenia.
The Journal of clinical psychiatry 2007;68(5):e12.
2007: Benjamin G Druss; John W Newcomer
Challenges and solutions to integrating mental and physical health care.
The Journal of clinical psychiatry 2007;68(4):e09.
2007: John W Newcomer; Jeffrey A Lieberman
Comparing safety and tolerability of antipsychotic treatment.
The Journal of clinical psychiatry 2007;68(3):e07.
2007: John W Newcomer
Antipsychotic medications: metabolic and cardiovascular risk.
The Journal of clinical psychiatry 2007;68 Suppl 4():8-13.
2007: John W Newcomer
Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
The Journal of clinical psychiatry 2007;68 Suppl 1():20-7.
2006: John W Newcomer
Medical risk in patients with bipolar disorder and schizophrenia.
The Journal of clinical psychiatry 2006;67(11):e16.
2006: John W Newcomer; Dan W Haupt
The metabolic effects of antipsychotic medications.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2006;51(8):480-91.
2006: John W Newcomer
Medical risk in patients with bipolar disorder and schizophrenia.
The Journal of clinical psychiatry 2006;67 Suppl 9():25-30; discussion 36-42.
2005: Charles Nemeroff; Jeffrey A Lieberman; Peter Weiden; Philip D Harvey; John W Newcomer; Alan F Schatzberg; Clinton D Kilts; David G Daniel
From clinical research to clinical practice: a 4-year review of ziprasidone.
CNS spectrums 2005;10(11 Suppl 17):1-20.
2005: Prakash S Masand; Larry Culpepper; David Henderson; Scott Lee; Kimberly Littrell; John W Newcomer; Natalie Rasgon
Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
CNS spectrums 2005;10(10):suppl14 1-15.
2005: John W Newcomer
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
CNS drugs 2005;19 Suppl 1():1-93.
2005: Dan W Haupt; Angela Luber; Justin Maeda; Angela K Melson; Julie A Schweiger; John W Newcomer
Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(1):184-91.
2004: John W Newcomer
Metabolic risk during antipsychotic treatment.
Clinical therapeutics 2004;26(12):1936-46.
2004: J Douglas Bremner; Meena Vythilingam; Eric Vermetten; Nadeem Afzal; Ahsan Nazeer; John W Newcomer; Dennis S Charney
Effects of dexamethasone on declarative memory function in posttraumatic stress disorder.
Psychiatry research 2004;129(1):1-10.
2004: John M Kane; Eugene J Barrett; Daniel E Casey; Christoph Correll; Alan J Gelenberg; Samuel Klein; John W Newcomer
Metabolic effects of treatment with atypical antipsychotics.
The Journal of clinical psychiatry 2004;65(11):1447-55.
2004: Peter L Zhang; Juan M Santos; John W Newcomer; Barbara A Pelfrey; Mark C Johnson; Gabriel de Erausquin
Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients.
Schizophrenia research 2004;71(1):137-44.
2004: Henry A Nasrallah; John W Newcomer
Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.
Journal of clinical psychopharmacology 2004;24(5 Suppl 1):S7-14.
2004: John W Newcomer; Henry A Nasrallah; Antony Loebel
The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
Journal of clinical psychopharmacology 2004;24(5 Suppl 1):S1-6.
2004: J Douglas Bremner; Meena Vythilingam; Eric Vermetten; George Anderson; John W Newcomer; Dennis S Charney
Effects of glucocorticoids on declarative memory function in major depression.
Biological psychiatry 2004;55(8):811-5.
2004: John W Newcomer
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
The Journal of clinical psychiatry 2004;65 Suppl 18():36-46.
2004: Daniel E Casey; Dan W Haupt; John W Newcomer; David C Henderson; Michael J Sernyak; Michael Davidson; Jean-Pierre Lindenmayer; Steven V Manoukian; Mary Ann Banerji; Harold E Lebovitz; Charles H Hennekens
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
The Journal of clinical psychiatry 2004;65 Suppl 7():4-18; quiz 19-20.
2003: Suzanne Craft; Sanjay Asthana; David G Cook; Laura D Baker; Monique M Cherrier; Kristina M Purganan; Colby Wait; Andreana Petrova; Shawn Latendresse; G Stennis Watson; John W Newcomer; Gerard D Schellenberg; Aaron J Krohn
Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype.
Psychoneuroendocrinology 2003;28(6):809-22.
2003: Pierre N. Tariot; Richard M Trosch; John W Newcomer
Managing psychosis in long-term care: treating the whole patient.
Journal of the American Medical Directors Association 2003;4(4 Suppl):H2-7.
2002: Dan W Haupt; John W Newcomer
Abnormalities in glucose regulation associated with mental illness and treatment.
Journal of psychosomatic research 2002;53(4):925-33.
2002: John W Newcomer; Dan W Haupt; Robert Fucetola; Angela K Melson; Julie A Schweiger; Benjamin P Cooper; Gregg Selke
Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.
Archives of general psychiatry 2002;59(4):337-45.
2002: Dawn I Velligan; John W Newcomer; Joseph Pultz; John G Csernansky; Anne Hoff; Roderick K Mahurin; Alexander Miller
Does cognitive function improve with quetiapine in comparison to haloperidol?
Schizophrenia research 2002;53(3):239-48.
2001: Dan W Haupt; John W Newcomer
Risperidone-associated diabetic ketoacidosis.
Psychosomatics 2001;42(3):279-80.
2001: John W Newcomer
Metabolic disturbances associated with antipsychotic use.
The Journal of clinical psychiatry 2001;62 Suppl 27():3-4; discussion 40-1.
2001: Dan W Haupt; John W Newcomer
Hyperglycemia and antipsychotic medications.
The Journal of clinical psychiatry 2001;62 Suppl 27():15-26; discussion 40-1.
2001: John W Newcomer; J H Krystal
NMDA receptor regulation of memory and behavior in humans.
Hippocampus 2001;11(5):529-42.
2001: Amy K Heffelfinger; John W Newcomer
Glucocorticoid effects on memory function over the human life span.
Development and psychopathology 2001;13(3):491-513.
2000: Nuri B Farber; Eugene H Rubin; John W Newcomer; DA Kinscherf; Philip Miller; John C Morris; John W Olney; Daniel W McKeel
Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis.
Archives of general psychiatry 2000;57(12):1165-73.
2000: John W Newcomer; N B Farber; J W Olney
NMDA receptor function, memory, and brain aging.
Dialogues in clinical neuroscience 2000;2(3):219-32.
1999: Suzanne Craft; Sanjay Asthana; John W Newcomer; Charles William Wilkinson; I T Matos; Laura D Baker; Monique M Cherrier; CP Lofgreen; Shawn Latendresse; Andreana Petrova; Stephen R Plymate; Murray A Raskind; K Grimwood; Richard C Veith
Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose.
Archives of general psychiatry 1999;56(12):1135-40.
1999: John W Olney; John W Newcomer; Nuri B Farber
NMDA receptor hypofunction model of schizophrenia.
Journal of psychiatric research 1999;33(6):523-33.
1999: Robert Fucetola; John W Newcomer; Suzanne Craft; Angela K Melson
Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia.
Psychiatry research 1999;88(1):1-13.
1999: Suzanne Craft; Sanjay Asthana; Gerard D Schellenberg; Monique M Cherrier; Laura D Baker; John W Newcomer; Stephen R Plymate; Shawn Latendresse; Andreana Petrova; Murray A Raskind; Elaine Peskind; CP Lofgreen; K Grimwood
Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.
Neuroendocrinology 1999;70(2):146-52.
1999: John W Newcomer; Gregg Selke; Angela K Melson; Tamara Hershey; Suzanne Craft; K Richards; A L Alderson
Decreased memory performance in healthy humans induced by stress-level cortisol treatment.
Archives of general psychiatry 1999;56(6):527-33.
1999: John W Newcomer; Nuri B Farber; Vesna Jevtovic-Todorovic; Gregg Selke; Angela K Melson; Tamara Hershey; Suzanne Craft; John W Olney
Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(2):106-18.
1999: John W Newcomer; Suzanne Craft; Robert Fucetola; S O Moldin; Gregg Selke; L Paras; RYAN MILLER
Glucose-induced increase in memory performance in patients with schizophrenia.
Schizophrenia bulletin 1999;25(2):321-35.
1999: Nuri B Farber; John W Newcomer; John W Olney
Glycine agonists: what can they teach us about schizophrenia?
Archives of general psychiatry 1999;56(1):13-7.
1998: John W Newcomer; Gregg Selke; Angela K Melson; J Gross; G P Vogler; Samuel Dagogo-Jack
Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans.
Archives of general psychiatry 1998;55(11):995-1000.
1998: Nuri B Farber; John W Newcomer; John W Olney
The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease.
Progress in brain research 1998;116():421-37.
1998: John W Newcomer; Suzanne Craft; K Askins; Tamara Hershey; Mark E Bardgett; John G Csernansky; A E Gagliardi; G Vogler
Glucocorticoid interactions with memory function in schizophrenia.
Psychoneuroendocrinology 1998;23(1):65-72.
1997: Samuel Dagogo-Jack; Gregg Selke; Angela K Melson; John W Newcomer
Robust leptin secretory responses to dexamethasone in obese subjects.
The Journal of clinical endocrinology and metabolism 1997;82(10):3230-3.
1996: Mark E Bardgett; John W Newcomer; G T Taylor
The effects of chronic corticosterone on memory performance in the platform maze task.
Physiology & behavior 1996;59(6):1111-5.
1996: John W Haller; Gary E Christensen; S C Joshi; John W Newcomer; Michael I Miller; John G Csernansky; Michael Vannier
Hippocampal MR imaging morphometry by means of general pattern matching.
Radiology 1996;199(3):787-91.
1996: Suzanne Craft; John W Newcomer; Stephen M Kanne; Samuel Dagogo-Jack; P Cryer; Y Sheline; J Luby; A Dagogo-Jack; A Alderson
Memory improvement following induced hyperinsulinemia in Alzheimer's disease.
Neurobiology of aging 1996;17(1):123-30.
1995: Pamela Keenan; M W Jacobson; R M Soleymani; John W Newcomer
Commonly used therapeutic doses of glucocorticoids impair explicit memory.
Annals of the New York Academy of Sciences 1995;761():400-2.
1995: Yvette I Sheline; Mark E Bardgett; J L Jackson; John W Newcomer; John G Csernansky
Platelet serotonin markers and depressive symptomatology.
Biological psychiatry 1995;37(7):442-7.
1994: John G Csernansky; John W Newcomer; K Jackson; L Lombrozo; K F Faull; R Zipursky; A Pfefferbaum; William O Faustman
Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
Psychopharmacology 1994;116(3):291-6.
1994: John W Newcomer; L S Miller; William O Faustman; Martin Wetzel; G P Vogler; John G Csernansky
Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
The British journal of psychiatry : the journal of mental science 1994;164(6):834-8.
1994: John W Newcomer; Suzanne Craft; Tamara Hershey; K Askins; Mark E Bardgett
Glucocorticoid-induced impairment in declarative memory performance in adult humans.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(4):2047-53.
1994: Mark E Bardgett; G T Taylor; John G Csernansky; John W Newcomer; B Nock
Chronic corticosterone treatment impairs spontaneous alternation behavior in rats.
Behavioral and neural biology 1994;61(2):186-90.
1994: J G Csernansky; John W Newcomer
Are there neurochemical indicators of risk for schizophrenia?
Schizophrenia bulletin 1994;20(1):75-88.
1993: Suzanne Craft; Samuel Dagogo-Jack; B V Wiethop; C Murphy; R T Nevins; S Fleischman; V Rice; John W Newcomer; P E Cryer
Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study.
Behavioral neuroscience 1993;107(6):926-40.
1993: Mark E Bardgett; C T Wrona; John W Newcomer; J G Csernansky
Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics.
European journal of pharmacology 1993;230(3):245-50.
1993: John G Csernansky; C T Wrona; Mark E Bardgett; T S Early; John W Newcomer
Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics.
Psychopharmacology 1993;110(1-2):145-51.
1992: John W Newcomer; William O Faustman; R B Zipursky; J G Csernansky
Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial.
Archives of general psychiatry 1992;49(9):751-2.
1992: John W Newcomer; S J Riney; S Vinogradov; John G Csernansky
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Psychiatry research 1992;41(3):191-202.
1992: John W Newcomer; S J Riney; S Vinogradov; John G Csernansky
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Psychopharmacology bulletin 1992;28(1):101-7.
1991: William O Faustman; James A Moses; D L Ringo; John W Newcomer
Left-handedness in male schizophrenic patients is associated with increased impairment on the Luria-Nebraska Neuropsychological Battery.
Biological psychiatry 1991;30(4):326-34.
1991: John W Newcomer; William O Faustman; H A Whiteford; James A Moses; John G Csernansky
Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients.
Biological psychiatry 1991;29(9):855-64.
1991: John G Csernansky; John W Newcomer; L S Miller; William O Faustman
Clinical factors that may confound the assessment of drug efficacy.
Psychopharmacology bulletin 1991;27(3):231-5.
1990: John W Newcomer; William O Faustman; W Yeh; John G Csernansky
Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia.
Psychiatry research 1990;31(3):243-50.